HYTN Welcomes U.S. Executive Order Initiating Cannabis Reclassification to Schedule III

Executive Summary

• The U.S. administration issued an executive order to begin reclassifying cannabis from Schedule I to Schedule III under the Controlled Substances Act.
• HYTN Innovations welcomes the move, noting its existing Health Canada Drug Establishment Licence (DEL), GMP certification for the U.S., and Cannabis Drug Licence (CDL) position it to capitalize on forthcoming federal pharmaceutical‑grade cannabis markets.
• The company highlights its export operations to the UK, Germany, and Australia as evidence of a ready platform for potential U.S. opportunities.

Key Details

• Executive order directs federal agencies to initiate the administrative process required to move cannabis to Schedule III, aligning it with substances such as acetaminophen‑codeine combos, testosterone, and certain anabolic steroids.
• Schedule III status would place medical cannabis under FDA and DEA oversight, imposing pharmaceutical‑level manufacturing, handling, research, prescribing, and importation requirements.
• HYTN’s CEO Elliot McKerr stated: “We welcome this development… we look forward to assessing how this process may shape future regulatory and commercial pathways.”
• HYTN currently holds:
• Health Canada Drug Establishment Licence (DEL) for non‑sterile pharmaceutical manufacturing.
• Certificate of GMP Conformity applicable to the United States.
• Cannabis Drug Licence (CDL), authorizing possession, production, packaging, labeling, and distribution of cannabis‑derived pharmaceuticals.
• The company operates a GMP platform with stability programs and exports regulated medical products to the United Kingdom, Germany, and Australia.
• HYTN believes its existing licences and infrastructure position it to evaluate and pursue opportunities arising from U.S. Schedule III reclassification.

Notable Quotes

“We welcome this development in the United States,” said Elliot McKerr, Chief Executive Officer of HYTN. “The executive order reflects a more structured and controlled regulatory approach toward cannabis that is aligned with established pharmaceutical frameworks.”